Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Director | January 15, 2026 | January 16, 2026 |
| Arcturus Therapeutics Holdings Inc.ARCT · Entity 5523 | Director | June 05, 2026 | June 15, 2026 |
| Arcturus Therapeutics Ltd.ARCT · Entity 160417 | Director | January 01, 2019 | January 02, 2019 |
| First Tracks Biotherapeutics, Inc.TRAX · Entity 4696 | Director | June 15, 2026 | June 17, 2026 |
| Immix Biopharma, Inc.IMMX · Entity 4958 | Director | May 22, 2026 | May 29, 2026 |
| Transcode Therapeutics, Inc.RNAZ · Entity 8499 | Director | June 14, 2024 | June 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date January 15, 2026 · Filed January 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,930 |
Ending reported balance
After 2026-01-15 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-01-15 · Exercise / conversion · Acquired 11,000 · Balance 20,930 Row 2 · 2026-01-15 · Sale · Disposed 9,290 · Balance 11,640 F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.595 to $48.54 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-01-15 · Sale · Disposed 1,710 · Balance 9,930 F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.625 to $48.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.11 · Expires 2031-01-17 | Direct | 0 |
Reported balance
After 2026-01-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-15 · Exercise / conversion · Disposed 11,000 · Balance 0 F3: The stock option is fully vested. F4: In addition to the options to purchase shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 70,104 shares of common stock, which options vest according to their terms. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.595 to $48.54 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.625 to $48.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The stock option is fully vested.
F4: In addition to the options to purchase shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 70,104 shares of common stock, which options vest according to their terms.
Arcturus Therapeutics Holdings Inc.
Report date June 05, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2036-06-05 | Direct | 15,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 15,000 · Balance 15,000 F1: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.
Arcturus Therapeutics Ltd.
Report date January 01, 2019 · Filed January 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 20,500 |
Reported balance
Holding disclosure · report date 2019-01-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 20,500 F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. |
| STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. F2: Vesting monthly over a two year period from August 24, 2018. |
| STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. F3: Vesting monthly over a one year period from August 24, 2018. |
| STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019.
F2: Vesting monthly over a two year period from August 24, 2018.
F3: Vesting monthly over a one year period from August 24, 2018.
First Tracks Biotherapeutics, Inc.
Report date June 15, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,960 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Exercise / conversion · Acquired 6,030 · Balance 15,960 F1: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Exercise / conversion · Disposed 6,030 · Balance 0 F1: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2: The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2: The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Immix Biopharma, Inc.
Report date May 22, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,342 |
Reported balance
After 2026-05-22 transaction · row 1
1 source rowRow 1 · 2026-05-22 · Grant · Acquired 6,250 · Balance 52,342 F1: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.78 · Expires 2036-05-22 | Direct | 12,500 |
Reported balance
After 2026-05-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-22 · Grant · Acquired 12,500 · Balance 12,500 F3: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date. |
| Common StockSEC Table I · non-derivative | Indirectby ALMA Life Sciences, LLC | 20,000 |
Reported balance
Holding disclosure · report date 2026-05-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20,000 F2: The Reporting Person is the Co-Founder and Co-Chief Executive Officer of Alma Life Sciences, LLC and may be deemed to beneficially own the securities held by Alma Life Sciences, LLC. The Reporting Person disclaims beneficial ownership of the common stock owned directly by Alma Life Sciences, LLC, except to the extent of her pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer.
F2: The Reporting Person is the Co-Founder and Co-Chief Executive Officer of Alma Life Sciences, LLC and may be deemed to beneficially own the securities held by Alma Life Sciences, LLC. The Reporting Person disclaims beneficial ownership of the common stock owned directly by Alma Life Sciences, LLC, except to the extent of her pecuniary interest therein.
F3: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.
Transcode Therapeutics, Inc.
Report date June 14, 2024 · Filed June 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.20 · Expires 2034-06-13 | Direct | 70,000 |
Reported balance
After 2024-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-14 · Grant · Acquired 70,000 · Balance 70,000 F1: Fifty percent (50%) of the shares subject to this option vested and became exercisable on January 1, 2024, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Fifty percent (50%) of the shares subject to this option vested and became exercisable on January 1, 2024, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Pfenex Inc.
Report date October 01, 2020 · Filed October 05, 2020
Section 16 reporting ended · disclosed 2020-10-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.49 · Expires 2029-02-28 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-10-01 · Other · Disposed 25,000 · Balance 0 F1: Upon the terms and subject to the conditions set forth in the Merger Agreement, each option with an exercise price equal to or less than the Cash Portion that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into a right to receive, with respect to each share of Issuer Common stock subject to such option, an amount in cash, without interest, equal to the excess, if any, of (i) the Cash Portion over the per share exercise price of such option, plus (ii) the CVR Portion (the "Option Consideration"). All Option Consideration will be paid without interest and less any applicable tax withholdings. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.43 · Expires 2030-05-08 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-01 · Other · Disposed 18,000 · Balance 0 F1: Upon the terms and subject to the conditions set forth in the Merger Agreement, each option with an exercise price equal to or less than the Cash Portion that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into a right to receive, with respect to each share of Issuer Common stock subject to such option, an amount in cash, without interest, equal to the excess, if any, of (i) the Cash Portion over the per share exercise price of such option, plus (ii) the CVR Portion (the "Option Consideration"). All Option Consideration will be paid without interest and less any applicable tax withholdings. F2: One hundred percent (100%) of the shares subject to the option shall vest and become exercisable on the date of the next annual meeting of the Issuer's stockholders (the "Annual Meeting") held after May 8, 2020, subject to the reporting person's continuing service through the date of the Annual Meeting. Notwithstanding the foregoing, one hundred percent (100%) of the shares subject to the option shall vest and become exercisable as of immediately prior to a Change in Control (as such term is defined in the Issuer's 2014 Equity Incentive Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the terms and subject to the conditions set forth in the Merger Agreement, each option with an exercise price equal to or less than the Cash Portion that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into a right to receive, with respect to each share of Issuer Common stock subject to such option, an amount in cash, without interest, equal to the excess, if any, of (i) the Cash Portion over the per share exercise price of such option, plus (ii) the CVR Portion (the "Option Consideration"). All Option Consideration will be paid without interest and less any applicable tax withholdings.
F2: One hundred percent (100%) of the shares subject to the option shall vest and become exercisable on the date of the next annual meeting of the Issuer's stockholders (the "Annual Meeting") held after May 8, 2020, subject to the reporting person's continuing service through the date of the Annual Meeting. Notwithstanding the foregoing, one hundred percent (100%) of the shares subject to the option shall vest and become exercisable as of immediately prior to a Change in Control (as such term is defined in the Issuer's 2014 Equity Incentive Plan).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 17, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | Exercise / conversionRestricted Stock Unit · Derivative | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001631486-26-000008 · form4-06172026_040614.xml · derivative · entry 2 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,030 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | Exercise / conversionCommon Stock | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001631486-26-000008 · form4-06172026_040614.xml · nonDerivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| June 05, 2026 Filed Jun 15, 2026 21:00 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001193805-26-000824 · e665579_4-marquet.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-06-05 F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| May 22, 2026 Filed May 29, 2026 21:05 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0001493152-26-026427 · ownership.xml · derivative · entry 3 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2036-05-22 F3 · derivative.exercise_date: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date. Read SEC document |
| May 22, 2026 Filed May 29, 2026 21:05 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-026427 · ownership.xml · nonDerivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,342 F1 · shares: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 12, 2026 Filed May 14, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $17.81 | $0.00 |
DisclosureSEC source: 0001631486-26-000006 · form4-05142026_040513.xml · derivative · entry 2 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2036-05-11 F3 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · balance_after: In addition to the options to purchase a total of 42,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 70,104 shares of common stock, which options vest according to their terms. Read SEC document |
| May 12, 2026 Filed May 14, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001631486-26-000006 · form4-05142026_040513.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 12, 2026 Filed Jun 12, 2026 20:08 UTC Amendment | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $17.81 | $0.00 |
DisclosureSEC source: 0001631486-26-000007 · form4a-06122026_080618.xml · derivative · entry 2 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2036-05-11 F3 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 12, 2026 Filed Jun 12, 2026 20:08 UTC Amendment | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001631486-26-000007 · form4a-06122026_080618.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001631486-26-000005 · form4-04222026_040407.xml · derivative · entry 10 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F6 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F8 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F8 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001631486-26-000005 · form4-04222026_040407.xml · derivative · entry 9 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,030 Underlying: Common Stock · 6,030 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F6 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F7 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F7 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 5,500 | $0.00 Strike: $11.75 | $0.00 |
DisclosureSEC source: 0001631486-26-000005 · form4-04222026_040407.xml · derivative · entry 8 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2036-01-06 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 16,510 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001631486-26-000005 · form4-04222026_040407.xml · derivative · entry 7 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,510 Underlying: Common Stock · 16,510 shares Expires 2035-01-06 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 16,510 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001631486-26-000005 · form4-04222026_040407.xml · derivative · entry 6 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,510 Underlying: Common Stock · 16,510 shares Expires 2034-01-02 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 10,600 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001631486-26-000005 · form4-04222026_040407.xml · derivative · entry 5 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires 2033-01-05 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 9,200 | $0.00 Strike: $8.14 | $0.00 |
DisclosureSEC source: 0001631486-26-000005 · form4-04222026_040407.xml · derivative · entry 4 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,200 Underlying: Common Stock · 9,200 shares Expires 2032-02-09 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $7.95 | $0.00 |
DisclosureSEC source: 0001631486-26-000005 · form4-04222026_040407.xml · derivative · entry 3 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-02-09 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 784 | $0.00 Strike: $6.99 | $0.00 |
DisclosureSEC source: 0001631486-26-000005 · form4-04222026_040407.xml · derivative · entry 2 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 784 Underlying: Common Stock · 784 shares Expires 2031-01-17 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 18:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $26.11 | $0.00 |
DisclosureSEC source: 0001631486-26-000002 · form4-01162026_010101.xml · derivative · entry 4 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires 2031-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested. F4 · balance_after: In addition to the options to purchase shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 70,104 shares of common stock, which options vest according to their terms. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 18:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 1,710 | $48.85 | $83,531.79 |
DisclosureSEC source: 0001631486-26-000002 · form4-01162026_010101.xml · nonDerivative · entry 3 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,930 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.625 to $48.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 18:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 9,290 | $48.12 | $446,999.50 |
DisclosureSEC source: 0001631486-26-000002 · form4-01162026_010101.xml · nonDerivative · entry 2 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,640 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.595 to $48.54 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 18:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 11,000 | $26.11 | $287,210.00 |
DisclosureSEC source: 0001631486-26-000002 · form4-01162026_010101.xml · nonDerivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,930 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001631486-26-000001 · form4-01082026_090143.xml · derivative · entry 2 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 5,500 | $0.00 Strike: $43.91 | $0.00 |
DisclosureSEC source: 0001631486-26-000001 · form4-01082026_090143.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2036-01-05 F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 20:57 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001641172-25-016113 · ownership.xml · derivative · entry 3 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2035-06-20 F1 · derivative.exercise_date: The Stock Option will vest in twelve (12) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 15, 2025 Filed Jun 17, 2025 22:32 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017590 · form4-06172025_100617.xml · derivative · entry 2 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,030 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 15, 2025 Filed Jun 17, 2025 22:32 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017590 · form4-06172025_100617.xml · nonDerivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,930 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| June 09, 2025 Filed Jun 12, 2025 00:01 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $12.54 | $0.00 |
DisclosureSEC source: 0001193805-25-000876 · e664622_4-marquet.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-06-09 F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 22:30 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001039 · form4-01072025_100114.xml · derivative · entry 2 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,030 Underlying: Common Stock · 6,030 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 22:30 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 16,510 | $0.00 Strike: $14.83 | $0.00 |
DisclosureSEC source: 0001415889-25-001039 · form4-01072025_100114.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,510 Underlying: Common Stock · 16,510 shares Expires 2035-01-06 F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 7, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 15, 2024 Filed Jun 19, 2024 00:17 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 3,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-017511 · form4-06192024_120639.xml · derivative · entry 2 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 15, 2024 Filed Jun 19, 2024 00:17 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 3,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-017511 · form4-06192024_120639.xml · nonDerivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:00 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $31.00 | $0.00 |
DisclosureSEC source: 0001193805-24-000826 · e663727_4-marquet.xml · derivative · entry 4 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-06-14 F3 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F3 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:00 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | Exercise / conversionDeferred Stock Units · Derivative | 3,131 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193805-24-000826 · e663727_4-marquet.xml · derivative · entry 3 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,131 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F1 · kind: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024. F1 · derivative.exercise_date: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024. F1 · derivative.expiration_date: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:00 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | Exercise / conversionCommon Stock | 3,131 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-24-000826 · e663727_4-marquet.xml · nonDerivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024. F1 · price: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:16 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001104659-24-072826 · tm2417512-4_4seq1.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: Fifty percent (50%) of the shares subject to this option vested and became exercisable on January 1, 2024, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 11, 2024 Filed Jun 21, 2024 21:45 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001493152-24-024825 · ownership.xml · derivative · entry 3 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2034-06-11 F1 · derivative.exercise_date: The Stock Option will vest in twelve (12) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 20, 2024 Filed May 20, 2024 21:25 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantCommon Stock | 21,155 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-020781 · ownership.xml · nonDerivative · entry 2 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,092 F3 · price: Received in exchange for shares of common stock of Nexcella, Inc. which were held by the Reporting Person, which entity was merged with and into the Issuer on May 20, 2024, with the Issuer continuing as the surviving entity. Read SEC document |
| May 15, 2024 Filed May 20, 2024 21:25 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantCommon Stock | 25,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-020781 · ownership.xml · nonDerivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,002 F1 · kind: Issued to replace prior awards held by the Reporting Person in Nexcella, Inc., in contemplation of the merger of Nexcella, Inc. and the Issuer, which became effective on May 20, 2024. F2 · shares: Restricted Stock Awards which will vest in thirteen (13) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:59 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001051 · doc4.xml · derivative · entry 2 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,030 Underlying: Common Stock · 6,030 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:59 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 16,510 | $0.00 Strike: $21.19 | $0.00 |
DisclosureSEC source: 0001209191-24-001051 · doc4.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,510 Underlying: Common Stock · 16,510 shares Expires 2034-01-02 F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 3, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 21:46 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 9,000 | $2.47 | $22,212.90 |
DisclosureSEC source: 0001493152-23-032150 · ownership.xml · nonDerivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Via ALMA Life Sciences, LLC Disclosed balance after: 20,000 Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 20:33 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 10,000 | $2.47 | $24,722.00 |
DisclosureSEC source: 0001493152-23-031838 · ownership.xml · nonDerivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Via ALMA Life Sciences, LLC Disclosed balance after: 11,000 Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 22:43 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 1,000 | $2.01 | $2,010.00 |
DisclosureSEC source: 0001493152-23-031708 · ownership.xml · nonDerivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Via ALMA Life Sciences, LLC Disclosed balance after: 1,000 Read SEC document |
| August 11, 2023 Filed Aug 14, 2023 20:15 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Options · Derivative | 20,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001493152-23-028469 · ownership.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-08-11 F1 · derivative.exercise_date: Options vest monthly over 12 months from the date of grant. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:09 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantDeferred Stock Units · Derivative | 3,131 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-23-001069 · e618807_4-marquet.xml · derivative · entry 2 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,131 Underlying: Common Stock · 3,131 shares Expires not disclosed F2 · derivative.exercise_price: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock F3 · derivative.exercise_date: Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F3 · derivative.expiration_date: Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:09 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 11,869 | $0.00 Strike: $34.92 | $0.00 |
DisclosureSEC source: 0001193805-23-001069 · e618807_4-marquet.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,869 Underlying: Common Stock · 11,869 shares Expires 2033-08-01 F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant; provided however, that the remaining unvested balance will vest and become fully exercisable at the Issuer's 2024 annual meeting of stockholders. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| May 19, 2023 Filed May 20, 2023 00:08 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001104659-23-062815 · tm2316383-5_4seq1.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2033-05-18 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full on December 31, 2023, subject to the Reporting Person's continued service at such time. Read SEC document |
| May 10, 2023 Filed May 10, 2023 22:12 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | GrantStock Option (Right to Buy) · Derivative | 9,500 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001104659-23-058581 · tm2315294-2_4seq1.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2033-05-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 10, 2024 and (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| January 06, 2023 Filed Jan 11, 2023 00:09 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 3,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002882 · doc4.xml · derivative · entry 2 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,900 Underlying: Common Stock · 3,900 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.